9087 ATS Enduring Evaluation

6. BEFORE taking this educational activity, how would you have rated your ability to: *This question is required.

Space Cell	0 - Not Relevant	1 - Low	2	3	4	5 - High
Integrate new information on IPF treatment into practice as it becomes available in your practice?	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 0 - Not Relevant	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 1 - Low	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 2	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 3	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 4	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 5 - High
Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 0 - Not Relevant	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 1 - Low	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 2	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 3	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 4	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 5 - High
Rate your confidence to decide when to stop or switch treatment in your practice?	Rate your confidence to decide when to stop or switch treatment in your practice?: 0 - Not Relevant	Rate your confidence to decide when to stop or switch treatment in your practice?: 1 - Low	Rate your confidence to decide when to stop or switch treatment in your practice?: 2	Rate your confidence to decide when to stop or switch treatment in your practice?: 3	Rate your confidence to decide when to stop or switch treatment in your practice?: 4	Rate your confidence to decide when to stop or switch treatment in your practice?: 5 - High
Identify and manage comorbidities associated with IPF in your practice?	Identify and manage comorbidities associated with IPF in your practice?: 0 - Not Relevant	Identify and manage comorbidities associated with IPF in your practice?: 1 - Low	Identify and manage comorbidities associated with IPF in your practice?: 2	Identify and manage comorbidities associated with IPF in your practice?: 3	Identify and manage comorbidities associated with IPF in your practice?: 4	Identify and manage comorbidities associated with IPF in your practice?: 5 - High

7. AFTER taking this educational activity, how would you have rated your ability to: *This question is required.

Space Cell	0 - Not Relevant	1 - Low	2	3	4	5 - High
Integrate new information on IPF treatment into practice as it becomes available in your practice?	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 0 - Not Relevant	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 1 - Low	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 2	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 3	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 4	Integrate new information on IPF treatment into practice as it becomes available in your practice?: 5 - High
Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 0 - Not Relevant	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 1 - Low	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 2	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 3	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 4	Confidence in discussing timing and rationale for starting antifibrotic therapy in your practice?: 5 - High
Rate your confidence to decide when to stop or switch treatment in your practice?	Rate your confidence to decide when to stop or switch treatment in your practice?: 0 - Not Relevant	Rate your confidence to decide when to stop or switch treatment in your practice?: 1 - Low	Rate your confidence to decide when to stop or switch treatment in your practice?: 2	Rate your confidence to decide when to stop or switch treatment in your practice?: 3	Rate your confidence to decide when to stop or switch treatment in your practice?: 4	Rate your confidence to decide when to stop or switch treatment in your practice?: 5 - High
Identify and manage comorbidities associated with IPF in your practice?	Identify and manage comorbidities associated with IPF in your practice?: 0 - Not Relevant	Identify and manage comorbidities associated with IPF in your practice?: 1 - Low	Identify and manage comorbidities associated with IPF in your practice?: 2	Identify and manage comorbidities associated with IPF in your practice?: 3	Identify and manage comorbidities associated with IPF in your practice?: 4	Identify and manage comorbidities associated with IPF in your practice?: 5 - High

*If yes or possibly considering changes, please check off what you intend to do differently or incorporate into your clinical management of patients as a result of this educational activity. *This question is required.

• Employ shared decision-making with my care team members
• More freely share information with my care team members
• Incorporate new information on IPF treatment into clinical practice
• Increase familiarity with new developments in the management of patients with IPF
• Increase efforts to identify and manage combordities in patients with IPF
• Discuss with patients the rationale for starting antifibrotic therapy and importance of starting early
• Improve routine monitoring and management of treatment-related side effects with patient involvement
• Educate patients on the importance of adherence to treatment for slowing disease progression
• Other, please specify Please enter an 'other' value for this selection.